Common Questions

The Truelove and Witts criteria remain the standard for defining acute severe ulcerative colitis (ASUC), incorporating stool frequency, blood, heart rate, temperature, hemoglobin, and ESR/CRP. Endoscopic (Mayo) scoring and disease extent (Montreal classification) further inform medical and surgical planning.

Indications include failure to respond to IV corticosteroids or rescue biologic/cyclosporine therapy within the expected window (typically 3-5 days), toxic megacolon, perforation, uncontrolled hemorrhage, and clinical deterioration despite maximal medical therapy. Early surgical consultation is recommended for all ASUC admissions.

Response is typically reassessed at day 3, using clinical criteria (such as the Oxford or Ho index) alongside CRP and stool frequency trends, to decide whether to continue rescue therapy or proceed to colectomy, delaying surgery in a non-responder increases perioperative risk.

A 3-stage approach (subtotal colectomy with end ileostomy, followed later by completion proctectomy with IPAA and loop ileostomy, then ileostomy closure) is standard for ASUC or malnourished/high-risk patients, while a 2-stage or modified 2-stage approach may be used in elective, medically optimized patients.

Preoperative biologic exposure, particularly recent high-dose or combination biologic therapy, is associated with increased postoperative infectious complication risk in some studies, which is a factor favoring a staged approach (subtotal colectomy first) over single-stage IPAA in this setting.

Predictors include pelvic sepsis, anastomotic leak, Crohn's disease diagnosed after pouch construction, chronic pouchitis, and poor preoperative sphincter function. Careful patient selection and minimizing anastomotic tension and ischemia at construction are key modifiable factors.

Chronic antibiotic-refractory pouchitis, especially with small bowel or perianal involvement not explained by surgical complications, raises suspicion for Crohn's disease of the pouch. Endoscopic and histologic evaluation, along with disease course, help differentiate the two, though overlap can make this diagnostically challenging.

Anti-TNF and other biologic agents are increasingly used for chronic antibiotic-refractory pouchitis and Crohn's-like disease of the pouch, extrapolating largely from IBD data given limited pouch-specific trial evidence, and are typically used after antibiotic therapy has failed.

A diverting loop ileostomy is standard after IPAA in most staged approaches to protect the pelvic anastomosis during healing, and is particularly favored in patients with risk factors for leak, malnutrition, steroid or biologic exposure, and technically difficult pelvic dissection.

Elective restorative proctocolectomy with IPAA, typically as a modified 2-stage or 3-stage procedure depending on risk factors, is standard for medically refractory disease, with segmental colectomy generally avoided given high rates of disease recurrence in remaining colon.

Longstanding extensive colitis carries increased colorectal cancer risk, and confirmed dysplasia, particularly high-grade or multifocal, is an indication for colectomy; surveillance colonoscopy protocols and chromoendoscopy are used to detect dysplasia earlier in longstanding disease.

Continent ileostomy is generally reserved for patients who are not IPAA candidates (e.g., poor sphincter function, prior failed pouch, or patient preference against a loop ileostomy stage), given its own distinct complication profile including valve slippage and higher revision rates.

Management ranges from percutaneous or transanal drainage with continued diversion for contained leaks to reoperation for uncontrolled sepsis, with the overall goal of pouch salvage where possible. Early recognition and aggressive source control are key to preserving long-term pouch function.